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Abstract: 
Misuse of (±)-threo-methylphenidate (methyl-2-phenyl-2-(piperidin-2-
yl)acetate; Ritalin®, MPH)  has long been acknowledged, but the 
appearance of MPH analogs in the form of ‘research chemicals’ has only 
emerged in more recent years. 4-Fluoromethylphenidate (4F-MPH) is one 
of these recent examples and this study presents the identification and 
analytical characterization of two powdered 4F-MPH products that were 
obtained from an online vendor in 2015. Interestingly, both products 
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
For Peer Review
appeared to have originated from two distinct batches given that one 
product consisted of (±)-threo-4F-MPH isomers whereas the second 
sample consisted of a mixture of (±)-threo and (±)-erythro 4F-MPH. 
Monoamine transporter studies using rat brain synaptosomes revealed that 
the biological activity of the 4F-MPH mixture resided with the (±)-threo- 
and not the (±)-erythro isomers based on higher potencies determined for 
blockage of dopamine (IC50 4F-MPHmixture = 66 nM vs. IC50 (±)-threo = 61 
nM vs. IC50 (±)-erythro = 8,528 nM) and norepinephrine (IC50 4F-MPHmixture 
= 45 nM vs. (±)-threo = 31 nM vs. IC50 (±)-erythro = 3,779 nM) uptake. 
In comparison, MPH was three times less potent than (±)-threo-4F-MPH at 
the dopamine transporter (IC50 = 131 nM) and around 2.5-times less 
potent at the norepinephrine transporter (IC50 = 83 nM). Both substances 
were catecholamine selective with IC50 values of 8,805 nM and >10,000 nM 
for (±)-threo-4F-MPH and MPH at the serotonin transporter. These findings 
suggest that the psychostimulant properties of (±)-threo-4F-MPH might be 
more potent in humans than MPH. 
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Abstract 
 
Misuse of (±)-threo-methylphenidate (methyl-2-phenyl-2-(piperidin-2-
yl)acetate; Ritalin®, MPH)  has long been acknowledged, but the appearance 
of MPH analogs in the form of ‘research chemicals’ has only emerged in more 
recent years. 4-Fluoromethylphenidate (4F-MPH) is one of these recent 
examples and this study presents the identification and analytical 
characterization of two powdered 4F-MPH products that were obtained from 
an online vendor in 2015. Interestingly, the products appeared to have 
originated from two distinct batches given that one product consisted of (±)-
threo-4F-MPH isomers whereas the second sample consisted of a mixture of 
(±)-threo and (±)-erythro 4F-MPH. Monoamine transporter studies using rat 
brain synaptosomes revealed that the biological activity of the 4F-MPH 
mixture resided with the (±)-threo- and not the (±)-erythro isomers based on 
higher potencies determined for blockage of dopamine uptake (IC50 4F-
MPHmixture = 66 nM vs. IC50 (±)-threo = 61 nM vs. IC50 (±)-erythro = 8,528 nM) 
and norepinephrine uptake (IC50 4F-MPHmixture = 45 nM vs. (±)-threo = 31 nM 
vs. IC50 (±)-erythro = 3,779 nM). In comparison, MPH was three times less 
potent than (±)-threo-4F-MPH at the dopamine transporter (IC50 = 131 nM) 
and around 2.5-times less potent at the norepinephrine transporter (IC50 = 83 
nM). Both substances were catecholamine selective with IC50 values of 8,805 
nM and >10,000 nM for (±)-threo-4F-MPH and MPH at the serotonin 
transporter. These findings suggest that the psychostimulant properties of (±)-
threo-4F-MPH might be more potent in humans than MPH. 
 
 
Introduction 
 
Methylphenidate (methyl-2-phenyl-2-(piperidin-2-yl)acetate; MPH; Ritalin®) is 
a substituted phenethylamine that was first synthesized in 1944 and 
subsequently recognized as a psychostimulant (Figure 1).[1,2] MPH acts 
primarily by inhibiting the re-uptake of dopamine and norepinephrine resulting 
in elevated concentrations of these monoamine neurotransmitters within the 
synaptic cleft.[3,4] MPH is widely used in the treatment of attention deficit 
hyperactivity disorder (ADHD), as the symptoms of this condition are believed 
to be associated with suppressed levels of these neurotransmitters.[5,6] 
Originally, it was marketed as a mixture of two racemates, consisting of 80% 
(±)-erythro and 20% (±)-threo isomers, but successive studies demonstrated 
that the pharmacologically active diastereomers are associated with the (±)-
threo form.[7-10] Subsequent studies focused on the separation of the two 
diastereomers and interconversion of (±)-erythro racemate to its (±)-threo 
counterpart. The (±)-threo racemate exists as two enantiomers, (+)-threo-
MPH (2R,2’R) and (-)-threo-MPH (2S,2’S), and the absolute stereochemistry 
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of the most pharmacologically active enantiomer of MPH ((+)-threo) has been 
characterized[11-13] and developed as a medication to treat ADHD in its own 
right.[14] There have also been efforts to prepare enantiomerically pure 
(2R,2’R)-(+)-threo-MPH.[7] In vivo, (±)-threo-MPH undergoes enantioselective 
metabolism, which results in substantial differences in the plasma 
concentrations of its isomers, depending on route of administration and 
formulation.[15] Methylphenidate is listed as a Schedule II substance in the 
1971 United Nations Convention on Psychotropic Substances.[16] In the 
United Kingdom (UK), it is controlled as a Class B substance under the 
Misuse of Drugs Act 1971.[17] In Ireland, it is controlled as a Schedule 2 
substance under the Misuse of Drugs Regulations, 1988.[18]  
 
Methylphenidate and an array of its analogs form a class of compounds that 
are well documented in the patent and scientific literature.[19-23] Some studies 
have focused on the evaluation of structure-activity relationships whereas 
others have studied these analogs for other therapeutic indications, including 
cocaine addiction, depression, fatigue-related disorders, cerebral palsy and 
fibromyalgia.[19-23] However, misuse of methylphenidate has been observed 
among recreational drug users, presumably due to its psychostimulant 
properties. For example, ingestion/insufflation of methylphenidate is popular 
among university students to increase concentration, improve alertness, or 
solely for recreational purposes.[24,25] In the last decade, several unregulated 
substances that are very closely related to methylphenidate have been 
launched on the new psychoactive substances (NPS) market. As with the 
majority of NPS launched by vendors, many of these methylphenidate 
analogs have already been described in the pharmaceutical research 
literature. For example, ethylphenidate, 3,4-dichloromethylphenidate (3,4-
CTMP), methylnaphthidate (HDMP-28), isopropylphenidate (IPP/IPPD) and 
propylphenidate are methylphenidate analogs that have been detected on the 
‘research chemicals’ market.[6,26] In April 2015, the UK government imposed a 
temporary drug control order (TCDO) on all these analogs.[27] Furthermore, 
the sale and supply of substances with psychoactive properties are now 
controlled in the UK under the newly introduced New Psychoactive 
Substances Act 2016.[28] Comprehensive analytical characterizations have 
recently been described for 4-methylmethylphenidate, 3,4-CTMP, 
ethylphenidate, 3,4-dichloroethylphenidate, N-benzyl-ethylphenidate and 
ethylnaphthidate (HDEP-28), respectively.[29] Recent studies from the UK 
associated ethylphenidate use to adverse reactions including deaths.[30-32] In 
addition, it was reported that injection was a common route of administration, 
thus adding the risk of harms associated with this method of administration. 
Interestingly, co-ingestion of ethanol and methylphenidate has been reported 
to form ethylphenidate in vivo by transesterfication.[26,33] In Ireland, the sale 
and supply of analogs of methylphenidate would be controlled under the 
Criminal Justice (Psychoactive Substances) Act 2010.[34]  
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4-Fluoromethylphenidate (4F-MPH) (Figure 1) is a methylphenidate analog 
that was developed within the pharmaceutical setting. However, in November 
2015, it was first notified by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) Early Warning System following its detection on 
the recreational market.[35] Previous in vitro studies indicated that the addition 
of a fluorine atom to the para-position of the phenyl ring in the 
methylphenidate parent structure led to slight increases in potency related to 
displacement of [3H]WIN-35,428 and [3H]dopamine uptake inhibition.[4] 
 
This study describes the analytical characterization of two powdered samples 
and a set of tablets of 4-fluoromethylphenidate that were obtained from the 
same vendor based in the United Kingdom in 2015. The study was triggered 
following the receipt of two powdered 4F-MPH samples from an online 
retailer. Various chromatographic, spectroscopic and mass spectrometric 
analysis methods were employed, followed by x-ray crystal structure analysis. 
One of the vendor samples was found to contain (±)-threo-4F-MPH, which 
was consistent with the expected racemate based on the current knowledge 
of the biological activity of (±)-threo-MPH. Unexpectedly, the analysis of the 
second sample revealed that it consisted of a mixture of (±)-threo and (±)-
erythro-4F-MPH. This suggested that the two powdered vendor products 
might have originated from different batches. The two racemates were 
isolated from the mixture, purified, and converted to HCl salts prior to full 
analytical characterization. In addition, 4F-MPH tablets were also obtained 
from the same vendor and analysed for the presence of the (±)-threo and/or 
(±)-erythro form. 
 
It was hypothesized that the distinct forms of 4F-MPH encountered in these 
products would result in different pharmacological properties similar to what 
has been reported for MPH, thus, potentially resulting in different effects in 
consumers. For this reason, the ability of the test drugs to inhibit uptake of 
[3H]dopamine, [3H]norepinephrine and [3H]serotonin was investigated using 
synaptosomal preparations from rat brain. The isolated diastereomeric 
racemates (±)-threo and (±)-erythro-4F-MPH, the (±)-threo/(±)-erythro mixture, 
and MPH were included to study the effects at dopamine transporters (DAT), 
norepinephrine transporters (NET) and serotonin transporters (SERT), 
respectively.   
 
Experimental  
 
Chemicals 
 
All reagents and dry solvents used in the syntheses were obtained from 
Sigma Aldrich Ltd (Arklow, Co. Wicklow, Ireland). LC-MS grade solvents were 
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obtained from Fisher Scientific (Dublin, Ireland). Preparative silica gel thin 
layer chromatography plates (UV254, GF 20 x 20 cm, 2000 microns) were 
obtained from Analtech (Newark, NJ, USA). Two powdered samples of 4-
fluoromethylphenidate (4F-MPH) and tablets were obtained from an online 
vendor based in the UK in 2015.  
 
Isolation of 4-fluoromethylphenidate (4F-MPH) diastereomers 
 
A solution of 4-fluoromethylphenidate (568 mg, vendor sample containing 
both diastereomers) in water (15 mL) was made basic with sodium hydroxide 
(pH 10-11). This was extracted with dichloromethane (2 x 10 mL). Drying 
(anhydrous magnesium sulphate) and removal of the solvent afforded a 
colorless oil (355 mg). Preparative TLC (silica gel, 2 mm; mobile phase: ethyl 
acetate; extraction solvent: ethanol) afforded two fractions, both colorless 
viscous oils (23 and 84 mg). The HCl salts were formed (2M hydrogen 
chloride in diethyl ether) and crystallized from ethanol for x-ray 
crystallography.  
 
(±)-threo-4F-MPH freebase (bottom band of preparative TLC) 
 
1H NMR (CDCl3) δ 7.36-7.22 (m; 2H; H-2’/6’), 7.14-6.98 (m; 2H; H-3’/5’), 3.70 
(s; 3H; CH3), 3.61 (d; J = 10.2 Hz; 1H; H-2), 3.25-3.13 (m; 2H; H-2’’ and one H 
from H-6’’), 2.75 (td; J = 12.0, 2.9 Hz; 1H; one from H-6’’), 1.76-1.69 (m; 1H; 
one H from H-4’’), 1.66-1.58 (m; 1H; one H from H-5’’), 1.46 (dddd; 1H; J = 
16.1, 12.4, 8.4, 3.8 Hz; one H from H-5’’), 1.33 -1.19 (m; 2H; one H each from 
H-4’’ and H-3’’) and 1.08-0.97 (m; 1H; one H from H-3’’) ppm; 13C NMR 
(CDCl3) δ 173.53 (C=O), 162.24 (d; JCF = 246.5 Hz; C-4’), 131.98 (C-1’), 
130.08 (d; JCF = 7.8 Hz; C-2’/6’), 115.63 (d; JCF = 21.5 Hz; C-3’/5’), 59.01 (C-
2’’), 57.07 (C-2), 52.32 (CH3), 46.69 (C-6’’), 29.29 (C-3’’), 25.43 (C-5’’) and 
24.05 (C-4’’) ppm; 19F NMR (CDCl3) δ -114.63 ppm.  
 
(±)-threo-4F-MPH hydrochloride  
 
Melting point: 202-204 oC. 1H NMR (DMSO) δ 7.38-7.32 (m; 2H; H-2’/6’), 7.28-
7.21 (m; 2H; H-3’/5’), 4.12 (d; J = 9.6 Hz; 1H; CH; H-2), 3.83-3.75 (m; 1H; CH; 
H-2’’) 3.32 (s; 3H; CH3), 3.28 (apparent d; J = 13.1 Hz; 1H; one H from H-6’’), 
2.96 (apparent t; J = 11.6 Hz; 1H; one H from H-6’’), 1.74-1.64 (m; 2H; one H 
each from H-4’’ and 5’’), 1.63-1.57 (m; 1H; one H from H-5’’), 1.47-1.38 (m; 
1H; one H from H-4’’) and 1.46-1.27 (m; 2H; H-3’’) ppm; 13C NMR (DMSO) δ 
171.48 (C=O), 162.21 (d; JCF = 244.9 Hz; C-4’), 131.03 (d; JCF = 8.4 Hz; C-
2’/6’), 130.52 (C-1’), 116.25 (d; JCF = 21.5 Hz; C-3’/5’), 56.93 (C-2’’), 53.05 
(CH3), 52.68 (C-2), 44.84 (C-6’’), 26.03 (C-3’’), 21.94 (C-5’’) and 21.55 (C-4’’) 
ppm; 19F NMR (DMSO) δ -113.87 ppm. HR-APCI-MS observed m/z 
252.139854 (theory [M + H]+: C14H19FNO2 m/z 252.139433, ∆ = 1.7 ppm). 
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(±)-erythro-4F-MPH freebase (top band of preparative TLC) 
 
1H NMR (CDCl3) δ 7.47-7.34 (m; 2H; H-2’/6’), 7.12-6.99 (m; 2H; H-3’/5’), 3.68 
(s; 3H; CH3), 3.56 (d; J = 10.3 Hz; 1H; H-2), 3.11 (td; J = 10.1, 2.2 Hz; 1H; H-
2’’), 3.01 (apparent d; J = 11.6 Hz; 1H; one H from H-6’’), 2.55 (td; J = 11.6, 
2.9 Hz; 1H; one H from H-6’’), 1.87-1.68 (m; 2H; one H from H-3’’ and H-4’’), 
1.66-1.58 (m; 1H; one H from H-5’’) and 1.55-1.25 (m; 3H; one H each from 
H-3’’, 4’’ and 5’’) ppm; 13C NMR (CDCl3) δ 172.84 (C=O), 162.50 (d; JCF = 
246.5 Hz; C-4’), 131.46 (C-1’), 130.36 (d; JCF = 7.9 Hz; C-2’/6’), 115.95 (d; JCF 
= 21.0 Hz; C-3’/5’), 59.09 (C-2’’), 57.04 (C-2), 52.06 (CH3), 46.94 (C-6’’), 
30.58 (C-3’’), 25.39 (C-5’’) and 24.22 (C-4’’) ppm; 19F NMR (CDCl3) δ -114.28 
ppm.  
 
(±)-erythro-4F-MPH hydrochloride  
 
Melting point: 198-200 oC.1H NMR (DMSO) δ ppm 7.51-7.44 (m; 2H; H-2’/6’), 
7.32-7.24 (m; 2H; H-3’/5’), 4.11 (d, J = 9.4 Hz; 1H; CH; H-2), 3.70-3.66 (m; 
1H; CH; H-2’’), 3.65 (s; 3H; CH3), 3.14 (apparent d, J = 13.0 Hz; 1H; one H 
from H-6’’), 2.83-2.80 (m; 1H; one H from H-6’’), 1.91-1.85 (m; 1H; one H from 
H-3’’), 1.82-1.69 (m; 2H; H-4’’/H-5’’), 1.68-1.59 (m; 2H; one H each from H-
4’’/H-5’’ and H-3’’) and 1.55-1.46 (m; 1H; one H from H-4’’/H-5’’) ppm; 13C 
NMR (DMSO) δ 171.36 (C=O), 162.81 (d; JCF = 244.5 Hz; C-4’), 131.55 (d; 
JCF = 8.5 Hz; C-2’/6’), 129.85 (C-1’), 116.65 (d; JCF = 21.6 Hz; C-3’/5’), 57.55 
(C-2), 53.55 (C-2’’), 53.00 (CH3), 45.26 (C-6’’), 27.39 (C-3’’), 22.10 (C-5’’) and 
21.93 (C-4’’) ppm; 19F NMR (DMSO) δ -113.80 ppm. HR-APCI-MS observed 
m/z 252.139659 (theory [M + H]+: C14H19FNO2 m/z 252.139433, ∆ = 0.9 ppm). 
 
 
Instrumentation 
 
Gas chromatography-mass spectrometry (GC-MS) 
 
Samples were prepared to give a 1 mg/mL solution in methanol and analyzed 
on an Agilent 6890N GC coupled to 5975 Mass Selective Detector (Agilent, 
Little Island, Cork, Ireland). A HP-ULTRA 1 column (12 m × 0.2 mm × 0.33 
µm) was used with helium carrier gas at a constant flow of 1 mL/min and a 
split ratio of 1:1. The injector was set at 250 °C and the transfer line at 280 °C. 
The initial oven temperature was 50 °C, held for 2 min, then ramped at 10 
°C/min to 100 °C with no hold time. The oven temperature was further ramped 
at 5 oC/min to 200 oC and then finally ramped at 20 oC/min to 295 oC with a 
hold time of 1 min. The mass spectra were collected after a 4.0 min solvent 
delay time. The ionization energy was set at 70 eV and the mass range was 
m/z 40-550. The total run time was 32.75 min. 
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Liquid chromatography-mass spectrometry (LC-MS) 
 
LC-MS analyses were performed on an Agilent 1100 HPLC system equipped 
with a G13795 degasser, G1312A BinPump, a G1313A ALS and G1316A 
column oven (COLCOM) (Agilent, Little Island, Cork). Separation was 
obtained on an Allure PFP Propyl column (5 µm, 50 x 2.1 mm) Restek 
(Bellefonte, PA, USA). Mobile phase A consisted of 0.1% formic acid in water, 
whereas, mobile phase B consisted of 0.1% formic acid in acetonitrile. The 
Agilent LC-MSD settings were as follows: positive electrospray mode, 
capillary voltage 3500 V, drying gas (N2) 12 L/min at 350 
oC, nebulizer gas 
(N2) pressure 50 psi, SIM m/z 252 and scan mode m/z 70-500, fragmentor 
voltage 50 and 110 V. Samples for LC-MS analysis were dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 10 
µg/mL. The injection volume was 5.0 and 10.0 µL, flow rate was 0.8 mL/min 
and the column temperature was 30 oC. Total run time was 25 min. The 
following gradient elution program was used: 0-2 min 2% B, followed by an 
increase to 60% B within 15 min, followed by another increase to 80% B 
within 18 min before returning to 2% B within 25 min. 
 
High resolution mass spectrometry (HR-MS) 
 
APCI experiments were carried out on a Bruker micrOTOF-Q III spectrometer 
interfaced to a Dionex UltiMate 3000 LC.  The Agilent tuning mix APCI-TOF 
was used for mass calibration. Masses were recorded over a range of m/z 
100-1600. Operating conditions were as follows: capillary voltage 4000 V, 
corona 4000 nA, nebulizer gas 2.0 bar, drying gas flow rate 3.0 L/min, drying 
gas temperature 100-200 oC, vaporizer temperature 100-400 oC. MicroTof 
control and HyStar software were used for data analysis.  
 
Nuclear magnetic resonance spectroscopy (NMR) 
 
The free base samples were prepared in deuterated chloroform (CDCl3) at a 
concentration of 20 mg/mL. The hydrochloride salt samples were prepared in 
deuterated dimethyl sulfoxide (DMSO-d6) at a concentration of 20 mg/mL. 
1H 
(600 MHz) and 13C (150 MHz) spectra were recorded on a Bruker AV600 
NMR spectrometer using a 5 mm TCI cryoprobe. 1H NMR spectra were 
referenced to an external TMS reference at δ = 0 ppm. 19F (376 MHz) spectra 
were recorded on a Bruker DPX400 NMR spectrometer and the external 
reference was trifluorotoluene set at δ = - 64 ppm. 
 
X-ray crystallography 
 
Data for samples (±)-erythro and (±)-threo-4F-MPH were collected on a 
Bruker APEX DUO using Cu Kα radiation (λ = 1.54178 Å) at 100(2) K (Oxford 
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Cobra Cryosystem) with a Mitegen holder. Bruker APEX[36] software was used 
to collect and reduce data, determine the space group. XT[37] was used to 
solve and XL[38] in OLEX 2[39] refine the structure. Absorption corrections were 
applied using SADABS 2014.[40] All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were assigned to calculated positions using a 
riding model with appropriately fixed isotropic thermal parameters. N-H 
hydrogens were located and refined with restraints and with the Uiso = 1.2Ueq 
of the carrier atom in both structures. In the threo-4F-MPH structure, the 
fluorophenyl ring was disordered in two positions with occupancies of 85/15%. 
Restraints were used in the model (DFIX, RIGU, SADI). 
 
Crystal Data for (±)-erythro-4F-MPH, C14H19NO2FCl (M =287.75 g/mol): 
monoclinic, space group P21/n (no. 14), a = 10.4556(5) Å, b = 8.5173(4) Å, 
c = 15.7304(7) Å, β = 90.6392(15)°, V = 1400.76(11) Å3, Z = 4, T = 100.0 K, 
µ(CuKα) = 2.510 mm-1, Dcalc = 1.364 g/cm3, 18265 reflections measured 
(10.106° ≤ 2Θ ≤ 137.044°), 2577 unique (Rint = 0.0376, Rsigma = 0.0232) which 
were used in all calculations. The final *R1 was 0.0355 (I > 2σ(I)) and wR2 was 
0.1108 (all data). CCDC No. 1503223. 
 
Crystal Data for (±)-threo-4F-MPH, C14H19ClFNO2 (M =287.75 g/mol): 
monoclinic, space group P21/n (no. 14), a = 11.289(3) Å, b = 7.2232(16) Å, 
c = 18.494(5) Å, β = 106.169(7)°, V = 1448.4(6) Å3, Z = 4, T = 100(2) K, 
µ(CuKα) = 2.428 mm-1, Dcalc = 1.320 g/cm3, 20393 reflections measured 
(8.286° ≤ 2Θ ≤ 136.614°), 2656 unique (Rint = 0.0813, Rsigma = 0.0513) which 
were used in all calculations. The final *R1 was 0.0525 (I > 2σ(I)) and wR2 was 
0.1357 (all data). CCDC No. 1503224. * R1 = Σ||Fo| − |Fc||/Σ|Fo|, wR2 = 
[Σw(Fo
2 − Fc
2)2/Σw(Fo
2)2]1/2. 
 
Infrared Spectroscopy 
 
IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR with 
Universal ATR sampling accessory (Perkin Elmer, Waltham, MA, USA). The 
wavelength resolution was set to 2 cm-1. IR spectra were collected in a range 
of 650 - 4000 cm-1 with 16 scans per spectrum. The IR data were processed 
using Spectrum Perkin Elmer Version 6.3.4 Software (Perkin Elmer, Waltham, 
MA, USA).  
 
Monoamine transporter assays 
 
Male Sprague-Dawley rats (250-300 g, Charles River Laboratories, 
Wilmington, MA, USA) were housed 2 per cage and maintained on a 12 h 
light-dark cycle. Food and water were provided ad libitum. Animal use 
procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals, and the Animal Care and Use Committee of 
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the Intramural Research Program of the National Institute on Drug Abuse 
(Baltimore, MD, USA). Rats were euthanized by CO2 narcosis and brains 
were processed to yield synaptosomes as previously described.[41,42] For 
uptake assays, synaptosomes were incubated with different concentrations of 
the test drugs in the presence of 5 nM [3H]dopamine, 10 nM 
[3H]norepinephrine, or 5 nM [3H]serotonin. The uptake assays were 
terminated by vacuum filtration and retained radioactivity was quantified by 
scintillation counting.  
 
 
Results and Discussion 
 
Manufacturers and entrepreneurs dedicated to the commercial exploration of 
‘research chemicals’ destined for recreational drug markets, are utilizing the 
scientific and patent literature to generate ideas for launching new 
compounds. Since methylphenidate and a series of its analogs have been 
well documented in the literature, e.g.[19-23], it was not surprising to see that 
several methylphenidate-based NPS have also been encountered on the 
‘research chemicals’ market. One of the more recent methylphenidate-based 
NPS was 4-fluoromethylphenidate (4F-MPH). 4F-MPH is one of the 
methylphenidate analogs described in the literature in studies evaluating ring 
substituted methylphenidate analogs as potential therapeutics for cocaine 
addiction and fibromyalgia.[19-21] 4F-MPH did not appear to have a history of 
human usage prior to its distribution online through vendors of ‘research 
chemicals’. 
 
In this study, two powdered samples and a set of tablets were obtained from 
the same vendor based in the United Kingdom in 2015. Initially, it was noticed 
that the two powdered products showed different solubility in solvents such as 
methanol and water. As the analyses progressed, it was noticed that one 
product contained the threo-racemate, whereas the other included a second 
compound suspected to represent a diastereomeric form based on similar 
mass spectra. Analysis by gas chromatography-mass spectrometry (GC-MS) 
suggested that this was the case and it was hypothesized that this product 
was most likely the racemic erythro- form of 4F-MPH. In order to investigate 
further, the 4F-MPH sample containing both diastereomers was dissolved in 
water and made alkaline with sodium hydroxide. This was extracted with 
dichloromethane, dried with anhydrous magnesium sulphate, followed by 
solvent removal to afford a colorless oil. Preparative thin-layer 
chromatography (TLC) afforded two fractions as colorless viscous oils. The 
hydrochloride salts were formed (2M hydrogen chloride in diethyl ether), 
crystallized from ethanol and subjected to extensive analytical 
characterization. 
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From examination of the methylphenidate synthesis literature, it seemed 
plausible that the presence of the erythro-racemate might have reflected a 
lack of purification at the end of the synthesis procedure. For example, one 
synthesis procedure employed for a range of methylphenidate analogs[4] 
involved the reaction of 2-phenylacetonitrile and 2-bromopyridine with 
potassium tert.-butoxide in tetrahydrofuran (THF). This led to the formation of 
a nitrile intermediate and a ketone by-product, which could be easily removed 
in the subsequent steps. The nitrile intermediate was hydrolysed under acidic 
conditions leading to the formation of an acetamide species. Hydrogenation of 
the pyridine ring to piperidine followed, leading to the formation of two racemic 
erythro- and threo acetamide intermediates. At this stage, the erythro species 
was present at a higher ratio compared to the threo-species. This mixture was 
then hydrolysed to form erythro- and threo-acetic acid entities. An 
epimerization process with potassium hydroxide flipped these ratios leading to 
a larger percentage of the threo-acetic acid intermediate. Esterification with 
methanol leads to the formation of the final threo/erythro acetate species, 
which was then purified by recrystallization to isolate the (±)-threo-racemate.[4] 
From this perspective, and provided a similar synthetic route was used by the 
manufacturers, failure to isolate the (±)-threo-racemate by appropriate 
recrystallization might have resulted in the presence of both racemates in the 
final product. An alternative explanation might be that the manufacturers 
decided to skip the recrystallization step on purpose.  
 
Analytical Features  
 
Gas chromatography mass spectrometry 
 
The gas chromatographic method used was abl  to achieve satisfactory 
separation between the (±)-threo- (18.13 min) and (±)-erythro- racemates 
(18.04 min) (Figure 2). The EI mass spectra obtained for both racemates were 
identical. The base peak was observed at m/z 84 and it is suggested that this 
was due to the formation of a tetrahydropyridinium species (C5H10N
+), 
following the loss of a methyl 4-fluorophenylacetate moiety from the molecular 
ion. This fragment was consistent with the EI mass spectral data for 
methylphenidate, ethylphenidate and 4F-MPH available in the literature.[26,43-
46] The fragment observed at m/z 190 was consistent with the formation of a 
4-fluorophenyl(piperidin-2-ylidene)methylium species (C12H13FN
+). The 
detection of m/z 168 may be rationalized by the loss of the tetrahydropyridine 
moiety from the parent structure, which gave rise to a radical cation and 
formation of a methyl fluorophenylacetate species (C9H8FO2
+). This fragment 
was also consistent with the EI-MS data for methylphenidate and 
ethylphenidate.[26,43-44] However, in the case of methylphenidate and 
ethylphenidate, this ion would be encountered at m/z 150 (methyl 
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phenylacetate moiety) and m/z 164 (ethyl phenylacetate moiety), respectively. 
The fragment at m/z 109 can be described by the formation of a tropylium ion, 
consistent with the formation of tropylium ion reported in the EI-MS of 
methylphenidate and ethylphenidate at m/z 91. The fragment at m/z 56 could 
represent the formation of a dihydroazetium ion. During GC analysis, a 
second product at 7.26 min was also observed in the chromatogram 
(Supporting Information) and it was believed that this product might have 
been a degradant resulting from the thermal decomposition of 4F-MPH within 
the GC system. This GC-induced reaction was thought to involve the loss of 
the tetrahydropyridine moiety and the formation of an enol tautomer of methyl 
4-fluorophenylacetate, which subsequently tautomerized to methyl 4-
fluorophenyl acetate. Interestingly, the formation of the GC-induced product, 
methyl 4-fluorophenyl acetate, was found to be slightly higher (53.6 %) in the 
chromatogram of the (±)-threo- 4FMPH racemate, compared to that of the (±)-
erythro- 4FMPH racemate (43.7%). This type of degradation was consistent 
with literature reports on methylphenidate and its analogs[29,47-48], however, 
the suggested identity remains tentative as a reference standard was not 
available. 
 
Liquid chromatography-mass spectrometry 
 
Analysis of both (±)-threo- and (±)-erythro- racemates of 4F-MPH using high 
performance liquid chromatography (HPLC) confirmed satisfactory separation 
for identification purposes. A retention time of 8.90 min was obtained for the 
(±)-erythro form, whereas a retention time of 9.81 min was obtained for the 
(±)-threo racemate (Figure 3). The electrospray ionization (ESI) single 
quadrupole mass spectra obtained from in-source collision-induced 
dissociation (CID) (fragmentor 110 V) of the 4F-MPH racemates shared two 
key ions. The suggested pathways are shown in Figure 3. In the mass spectra 
of both racemates, the fragment observed at m/z 252 represented the 
protonated molecule with 100% relative abundance. The product ion observed 
at m/z 84 might have represented a loss of the methyl 4-fluorophenylacetate 
moiety from the protonated molecule resulting in the formation of a 
tetrahydropyridinium species (C5H10N
+) and this was also present at 
approximately 95% abundance.  
 
Nuclear magnetic resonance spectroscopy (NMR) 
 
The chemical structures of the (±)-threo- and (±)-erythro- 4F-MPH racemates 
and powdered vendor samples were elucidated using both one-dimensional 
and two-dimensional NMR experiments (Figure 4, Supporting Information). 
The NMR spectra associated with the 4F-MPH HCl salt forms of the (±)-
erythro- and (±)-threo- racemates shared similar characteristics but significant 
differences could also be observed between some of the proton and carbon 
Page 12 of 26
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12
chemical shifts that facilitated differentiation between the racemates. For 
example, in the 1H spectrum of the (±)-erythro- racemate, the signals 
associated with the protons on the aromatic ring were observed as multiplets 
between 7.51-7.44 and 7.32-7.24 ppm. However, in the spectrum of the (±)-
threo- counterpart these proton resonances were shifted upfield to 7.38-7.32 
and 7.28-7.21 ppm, respectively. Furthermore, the proton signal for the methyl 
group of the (±)-threo- racemate was shifted upfield (3.32 ppm) compared to 
the same signal associated with the (±)-erythro racemate (3.65 ppm). The 
proton environment around the piperidine ring provided further distinguishing 
features. For example, in the 1H spectrum of the (±)-erythro- racemate, the 
proton signals associated with H-2” were observed as a multiplet between 
3.70-3.66 ppm. The same proton resonances in the (±)-threo- counterpart 
were also observed as a multiplet but were shifted downfield to 3.83-3.75 
ppm. Moreover, one proton associated with H-6” was observed as a doublet 
at 3.14 ppm in the proton spectrum of (±)-erythro- 4F-MPH. In comparison, 
the same proton signal in the (±)-threo- counterpart was shifted downfield and 
observed at 3.28 ppm (Figure 4). The second proton associated with H-6” 
also provided a distinguishing feature as it appeared as a triplet at 2.96 ppm 
in the (±)-threo- spectrum. However, the same proton signal in the (±)-erythro- 
counterpart was observed as a multiplet between 2.83-2.80 ppm. 
 
Some distinguishing features were also observed in the 13C NMR spectra 
(Supporting Information). For example, the 13C spectrum of the (±)-erythro- 
racemate revealed the carbonyl chemical shift at 171.36 ppm, whereas the 
same signal was observed at 171.48 ppm in the spectrum of the (±)-threo- 
counterpart. The aromatic region also provided distinct differences. In the 
spectrum of the (±)-erythro- racemate, the aromatic carbon signals (C-2’/6’, C-
3’/5’) were observed at 131.55 and 116.65 ppm. In the spectrum of the (±)-
threo- racemate, the same carbon signals were shifted upfield to 131.03 and 
116.21 ppm, respectively. However, another aromatic carbon signal (C-1’) 
was observed at 129.85 ppm in the (±)-erythro- spectrum, whereas the same 
carbon signal was shifted downfield and observed at 130.52 ppm in the (±)-
threo- spectrum. Moreover, the carbon of the methine group (C-2) was 
observed at 57.55 ppm in the spectrum of the (±)-erythro- racemate, which 
shifted upfield in the (±)-threo- counterpart and observed at 52.68 ppm. The 
piperidine carbon (C-2”) was observed at 53.55 ppm in the spectrum of the 
(±)-erythro- racemate, which shifted downfield in the (±)-threo- counterpart 
and observed at 56.93 ppm. In general, all carbon signals associated with the 
piperidine ring (44.84, 26.03, 21.94 and 21.55 ppm) were shifted upfield in the 
(±)-threo- spectrum compared to the same signals in the (±)-erythro- spectrum 
(45.26, 27.39, 22.10 and 21.93 ppm). The mixture contained the 
characteristics of both racemates. 
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X-Ray crystallography 
 
Both salts were crystallized from a water/ethanol mixture to give colorless 
needle shaped crystals. The crystal structures of both diastereomers are 
shown in Figures 5A and 5B. Both crystallized in the monoclinic space group 
P2(1)/n as the chloride salt. The (±)-erythro salt is shown as the (R,S)-
enantiomer (C2, C3) and the (±)-threo as the (S,S) enantiomer. As these 
molecules crystallized in a centrosymmetric space group, the inverse 
enantiomer was also equally present. The piperidine ring in both compounds 
was in the chair conformation. In both diastereomers, the piperidine was 
substituted in an equatorial position. The plane of piperidine ring to the 
fluorophenyl ring was 69.9° in the erythro and almost orthogonal at 84.5° in 
the threo salt. Each NH2 group was involved in hydrogen bonding. In the 
erythro salt the Cl- anion was strongly hydrogen bound to two NH2 groups 
(N1bCl1, 3.0704(12)Å, 170.1(15)°; N1bCl1#4, 3.2414(12)Å, 146.8(16)°, 
symmetry transformation #4 = 1-x, 1-y, 1-z) with the carbonyl oxygen more 
loosely held by weak C-H interactions (C3bO1#1, 3.3239(17)Å, 150°, 
symmetry transformation #1 = -x, 1-y, 1-z). This formed a symmetric dimer 
(Supporting Information). The threo salt also displayed NHbCl interactions 
(N1bCl1 3.134(2)Å, 167(3)°; N1bCl1#1 3.215(2)Å, 164(2)°, symmetry 
transformation #1 = 3/2-x, 1/2+y, -1/2-z). However, N1 formed a bifurcated 
hydrogen bond to the carbonyl oxygen (N1bO1#1 3.011(3)Å, 113(2)°). Unlike 
the erythro salt, the threo salt formed an extended ribbon parallel to the b –
axis (Supporting Information) These structural motifs are also seen in similar 
congeners which also form hydrogen bonded dimers or ribbons extending 
parallel to the b-axis.[49] 
 
Infrared spectroscopy 
 
The (±)-threo- and (±)-erythro- racemates of 4F-MPH were also subjected to 
analysis by infrared (IR) spectroscopy. The IR spectra associated with the 4F-
MPH HCl salt forms of the (±)-erythro- and (±)-threo- racemates shared 
similar characteristics although one difference was observed that facilitated 
differentiation (Supporting Information). The absorbance for the carbonyl 
group was observed at 1743 cm-1 for the (±)-threo- racemate compared to 
1726 cm-1 for the (±)-erythro- racemate. The vendor sample consisting of both 
racemates contained two carbonyl absorbance values consistent with those of 
the isolated  (±)-erythro- and (±)-threo- 4FMPH racemates. The second 
powdered vendor sample and the tablet shared the same characteristics as 
those of the (±)-threo- 4FMPH racemate. It was encouraging to observe that 
the infrared spectroscopic analysis was able to provide an important 
distinguishing feature between the 4F-MPH racemates, which would be 
beneficial when working within a forensic science laboratory setting.  
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Monoamine transporter activity 
 
When the analytical investigation revealed that two distinct 4F-MPH products 
were present, further questions arose about the potential for distinct 
pharmacological properties associated with the individual (±)-threo- and (±)-
erythro-form of 4F-MPH. Figure 6 shows the effects of the (±)-threo/erythro 
mixture, (±)-threo-4F-MPH, (±)-erythro-4F-MPH and methylphenidate (MPH) 
on the uptake of [3H]dopamine (DA), [3H]norepinephrine (NE) and 
[3H]serotonin (5-HT) by their respective transporters DAT, NET and SERT 
(Figure 6A-6D). The corresponding IC50 values for inhibition of uptake are 
provided in Table 1 and MPH was included for comparison. As revealed from 
the dose response curves, all test drugs were fully effective uptake inhibitors 
at DAT and NET, with little activity at SERT, thus, displaying catecholamine 
selectivity.  
 
The 4F-MPH mixture was about twice as potent as MPH at DAT and NET, 
although addition of the fluorine atom to the 4-position of the phenyl ring did 
not increase potency at SERT. Importantly, the data shown in Table 1 indicate 
that the biological activity of the 4F-MPH mixture predominantly resided with 
the (±)-threo- and not the (±)-erythro isomers given that higher potencies were 
determined for dopamine uptake (IC50 threo = 61 nM vs. IC50 erythro = 8,528 
nM) and norepinephrine uptake (IC50 threo = 31 nM vs. IC50 erythro = 3,779 
nM) at DAT and NET, respectively. The reduced activity of (±)-erythro isomers 
at DAT has been reported previously on other ring-substituted analogs.[4] 
Previous investigations also demonstrated that (±)-threo-4F-MPH showed 
nanomolar binding affinity toward DAT (IC50 = 35 nM, [
3H]WIN-35,428) and 
that it inhibited [3H]dopamine uptake via DAT in rat brain synaptosomal 
preparations (IC50 = 142 nM)
[4] consistent with the findings reported in this 
study. Consistent with the data shown in Table 1, (±)-threo-4F-MPH did not 
show any appreciable binding affinity at SERT (IC50 > 10 µM, [
3H]citalopram). 
Furthermore, (±)-threo-4F-MPH was shown to be about three times more 
potent than MPH in a drug discrimination assay.[50] Overall, it appears that the 
acetate group and the piperidine ring must be oriented in the opposite 
direction for the drugs to interact optimally with transporter proteins.  
 
Conclusion 
 
The analytical characterization of two 4F-MPH powders obtained from the 
same vendor of ‘research chemicals’ revealed the presence of (±)-threo 
isomers in one and a mixture of (±)-threo / (±)-erythro-4F-MPH racemates in 
the other, which suggested a failure to isolate the (±)-threo-racemate that may 
have formed during the synthesis procedure of the main (±)-threo product. 
Various chromatographic, spectroscopic and mass spectrometric platforms 
were employed followed by x-ray crystal structure analysis. (±)-threo-4F-MPH 
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was shown to be more potent than methylphenidate in its ability to inhibit 
uptake of [3H]dopamine and [3H]norepinephrine into rat brain synaptosomes, 
with significantly less activity associated with inhibition of the serotonin 
transporter. The significantly reduced potency of  (±)-erythro-4F-MPH was 
consistent with (±)-erythro-MPH and other (±)-erythro-MPH analogs reported 
in the literature. These findings suggest that the psychostimulant properties of 
(±)-threo-4F-MPH might be more potent in humans than MPH. Since the 
biological activity resides in the (±)-threo form, it is anticipated that other 
MPH-derived ‘research chemicals’ on the market might also display this 
configuration. 
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Figure 1. Chemical structures of methylphenidate, (±)-threo-racemate and (±)-erythro-racemate of 4-
fluoromethylphenidate  
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Figure 2. A-E: Gas chromatographic (GC) separation obtained for the isolated (±)-threo-racemate, isolated 
(±)-erythro-racemate of 4F-MPH and vendor samples. F-G: Electron ionization mass spectra obtained for the 
isolated (±)-threo- and (±)-erythro- racemates of 4F-MPH. H: Proposed fragmentation pattern for both 
racemates.  
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Figure 3. A-E: HPLC separation achieved for the isolated (±)-threo-racemate, isolated (±)-erythro-racemate 
and vendor samples of 4F-MPH. F-G: Product ion spectra obtained for isolated (±)-threo- and (±)-erythro- 
racemates of 4F-MPH obtained from in-source collision induced dissociation at increased fragmentor voltage 
(110 V). H: Proposed fragments for both racemates.  
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Figure 4. 1H NMR spectra obtained for the mixed 4F-MPH product, the isolated (±)-threo-racemate and 
isolated (±)-erythro-racemates of 4F-MPH.  
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Figure 5. A: Structure of (±)-erythro and B: (±)-threo salts of 4F-MPH. Atomic displacement parameters 
shown at 50% probability and hydrogen atoms drawn as spheres of arbitrary radius. In B, only the major 
disordered fluorophenyl moiety is shown.  
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Figure 6. Effects of 4-fluoromethylphenidate isomers (4F-MPH) and comparison with methylphenidate (MPH) 
on inhibition of uptake at DAT, NET, and SERT in rat brain synaptosomes. Synaptosomes were incubated 
with different concentrations of test drugs in the presence of 5 nM [3H]dopamine (A, for DAT), 10 nM 
[3H]norepinephrine (B, for NET), or 5 nM [3H]serotonin (C, for SERT). Data are percentage of 
[3H]transmitter uptake expressed as mean ± s.e.m. for n = 3 experiments.  
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Table 1. Effects of 4-fluoromethylphenidate (4F-MPH) and methylphenidate (MPH) on 
transporter-mediated uptake in rat brain synaptosomes 
a
 
Test Drug [
3
H]DA  
uptake via DAT IC50 
(nM) 
[
3
H]NE  
uptake via NET IC50 
(nM) 
[
3
H]5-HT  
uptake via SERT IC50 
(nM) 
Diastereomeric 
mixture of 4F-MPH 
66.35 ± 3.27 44.6 ± 4.17 >10,000 
(±)-threo-4F-MPH 60.96 ± 4.6 30.68 ± 2.64 8,805 ± 2475 
(±)-erythro-4F-MPH 8,528 ± 1753 3,779 ± 570.5 >10,000 
MPH 131.0 ± 14.2 82.85 ± 11.145 >10,000 
a
 Data are expressed as nM concentrations (mean ± SD) for n = 3 separate experiments 
performed in triplicate. For dose-response curve, see Figure 6. 
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